Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
ABECB, acute, added, administered, againstH, alliancesfocused, America, Andorra, annum, antibacterial, antimicrobial, appraisal, appraise, approach, April, arena, Austria, Belgium, bioequivalence, Biotech, bridge, British, broader, build, building, byHelicobacter, California, CAP, CEO, CFO, chemical, chronic, commitment, committed, communicated, comparator, comparing, conclusion, Concurrent, consummated, country, DARPA, declared, deformylase, degree, Denmark, derived, exacerbation, expand, facility, FACTIVE, fail, finite, Finland, fluoroquinolone, forgiven, France, Francisco, Gary, gemifloxacin, genesoft, Germany, good, goodwill, Greece, growing, growth, hand, hit, Iceland, implementation, improved, indefinite, infrastructure, inhibitor, intangible, integrate, intrinsic, investigational, Ireland, Italy, IV, joint, Kingdom, Korea, launch, lease, led, lesser, LG, liability, life, Luxembourg, Marino, marketplace, medical, merger, mesylate, metalloenzyme, mild, mix, moderate, Monaco, month, NDA, NIH, North, Norway, November, ofClostridium, organism, organization, Oscient, outcome, owed, partnership, Pasteur, patent, Patou, PDF, pending, peptide, permanent, permit, Pharmco, plant, play, pneumonia, pneumoniae, point, Portugal, preliminary, processed, promissory, prospective, proximate, proxy, pursue, pursuing, quinolone, randomized, rash, ready, recruit, registered, relevant, Reorganization, respiratory, retroactively, safe, sample, San, satisfaction, SB, sellin, serve, shift, sought, South, space, Spain, submit, substance, sufficient, summer, supplement, Supplemental, supply, Sweden, Switzerland, tangible, team, testing, thirty, tract, trading, treatClostridium, unable, undergo, undiscounted, unmet, vacate, valuation, Vatican
Removed:
abandoned, acceptable, acquire, advancement, agent, annotate, annually, antifungal, approximate, Astra, biological, biology, Candida, carryforward, case, Center, characterization, cloning, collaborator, collectively, commenced, compound, Creighton, dilute, divested, earlier, employ, employed, enabled, entering, entitled, essential, established, exceed, exceeded, excluding, exclusively, exercised, fluctuate, fluctuated, formation, full, functional, Hassle, Helicobacter, invest, issuing, level, maintained, maintenance, manner, maximum, met, microbial, natural, negotiation, nonowner, osteoporotic, PathoGenomeTM, peptic, positional, potentially, proprietary, protected, public, ranging, reducing, repayable, resistant, return, revised, satisfy, Schering, scientific, seek, sequence, sheet, Staph, suitable, survival, terminated, trait, treating, unique, unit, University, unsponsored, utilized, validate, worldwide, wrote
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 License and Option Agreement
- 10.2 Amendment No 1 to License and Option Agreement
- 10.3 Amendment No 2 to License and Option Agreement
- 10.4 Amendment No 3 to License and Option Agreement
- 10.5 Letter Agreement
- 10.6 Amendment to Employment Agreement
- 10.7 Amendment to Employment Agreement
- 10.8 Letter Agreement
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
- 99.1 Risk Factors
OSCI similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLET ACT OF 2002
Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Senior Vice President and Chief Financial Officer of Oscient Pharmaceuticals Corporation (the “Company”) does hereby certify that to my knowledge:
1) | the Company’s Report on Form 10-Q for the quarter ended March 27, 2004, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2) | the information contained in the Company’s Report on Form 10-Q for the quarter ended March 27, 2004, fairly presents, in all material respects, the financial condition and results of operations of the Company. |
By: | /s/ Stephen Cohen | |
Stephen Cohen | ||
Senior Vice President & Chief Financial Officer | ||
Dated: May 11, 2004 |